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Organism & disease 
Mannheimia haemolytica (formerly Pasteurella haemolytica Biotype A) is a Gram-negative, non-motile, 
non-spore-forming, facultative anaerobic, weakly hemolytic coccobacillus, and a member of the family 
Pasteurellaceae. It is a common inhabitant of the nasopharynx of cattle and the major cause of severe, 
often fatal, fibrinous pleuropneumonia in bovine respiratory disease especially in weaned, stressed, beef 
calves.  
 
Vaccine history 
Attempts to make vaccines against what was then Bacillus bovisepticus go back as early as the 1920s 
where there was no distinction between what would become M. haemolytica  and what would become 
Pasteurella multocida. With separation of those two bacteria and understanding that in cattle, M. 
haemolytica appeared to be the more important of the two bacteria in bovine respiratory disease (BRD), 
attempts to make vaccines were undertaken. Prior to the 1990s, bacterins were the only M. haemolytica 
vaccines available, and studies found that they were either generally ineffective or even enhanced 
disease in vaccinated cattle. Those negative findings along with the discovery of M. haemolytica 
leukotoxin as an important virulence factor and demonstration that immunity requires antibodies to 
leukotoxin and to surface antigens led to the development of new vaccines. In addition, the latter finding 
led to studies of various bacterial components to determine which surface antigens may be of 
importance. 
 
Virulence factors/potential immunogens 
Targeted areas of M. haemolytica study have been capsule, lipopolysaccharide, various adhesins, 
extracellular enzymes, outer membrane proteins, and leukotoxin (Table 1). Research has resulted in a 
database of information for understanding virulence factors, immune responses to the bacterium and 
potential immunogens that could enhance vaccine efficacy.   
 
Vaccines 
The importance of immunity to leukotoxin and to surface antigens in stimulating immunity led to studies 
of various types of potential vaccines and, in some cases, those studies led to marketing of newer 
vaccines. Vaccine studies have focused on individual native or recombinant antigens, bacterial extracts, 
live-attenuated or mutant organisms, culture supernatants, combined bacterin-toxoids, outer membrane 
vesicles, and bacterial ghosts (Table 2). Efficacy of most of these potential or marketed vaccines can be 
shown following experimental M. haemolytica challenge; however, efficacy in field trials is harder to 
determine due to the complexity of factors and etiologic agents involved in naturally occurring BRD. 
Current commercial vaccines are composed primarily of culture supernatant, bacterin-toxoid, or live 
mutant bacteria. Several of those can be augmented experimentally by addition of recombinant 
leukotoxin, sialoglycoprotease, or specific outer membrane proteins, and chimeric proteins composed of 
leukotoxin and surface antigens have been studied.      
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Table 1. Virulence factors, immunogens and potential immunogens of M. haemolytica   
Antigen Origin or source Virulence Factor Immunogenic 
Capsule Surface Antiphagocytic 
Adhesin 
Weak 
Filamentous 
hemagglutinin 
Membrane Adhesin Strong 
Fimbria Surface Adhesin Strong 
Gs60 Outer membrane and 
extracellular 
Unknown Strong 
IgA1 & IgA2 proteases Secreted Unknown  Moderate 
Leukotoxin Secreted Leukocyte necrosis & 
apoptosis 
Strong 
Lipopolysaccharide Surface Pro-inflammatory 
compound 
LipidA –Weak 
Polysaccharide - 
Moderate 
Lipoprotein 1 Membrane Adhesin Moderate 
Metaloproteases secreted enzymatic unknown 
N-acety-D-gluosamine Surface Adhesion Unknown 
Neuraminidase Extracellular Hydrolyzes sialic acid 
residues on cell surfaces 
Moderate 
OmpA Outer membrane Adhesin 
Binds lactoferrin 
Strong 
OmpD15 (Omp85) Outer membrane Unknown Weak 
OmpP2 Outer membrane Unknown Weak 
PlpE Outer membrane Unknown Strong 
PlpF Outer membrane Unknown Strong 
Serotype 1-specific 
antigen 
Outer membrane Possible adhesin Strong 
Sialoglycoprotease Extracellular Cleaves cell surface 
glycoproteins 
Strong 
Transferrin binding 
proteins A & B 
Outer membrane Remove iron from 
transferrin 
Strong 
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Table 2. Various Mannheimia haemolytica vaccines tested under experimental and field trials  
 
Vaccine type 
 
Timeframe 
Efficacy Commercially 
available Experimental Field 
Bacterin Prior to 
1990s 
Variable No No longer 
Sodium Salicylate 
extract 
1980s Variable Unknown No 
Potassium 
thiocyanate extract 
1980s Variable Unknown No 
Saline extract 1980s Efficacious  Unknown  No 
Live - attenuated 1980s Efficacious  Efficacious or 
ineffective 
No longer 
Live – streptomycin-
dependent 
1985-
present 
Variable Efficacious or 
ineffective 
Parenteral or 
intranasal vaccination 
Culture supernatant 1988 to 
present 
Efficacious  Variable Yes 
Bacterin toxoid 1989 to 
present 
Efficacious Variable Yes 
Capsular 
polysaccharide 
1990s Variable or 
poor 
Unknown No 
Proprietary extract 1990s Efficacious Somewhat 
efficacious 
No longer 
Recombinant 
chimeric protein 
2001-
present 
Partially 
efficacious  
Unknown  No 
Ghosts 2003 Efficacious  Unknown No 
Recombinant single 
protein 
2003-3006 Partially 
efficacious 
Unknown No 
LKT-deficient mutant 2012-2013 Efficacious Unknown No 
Outer membrane 
vesicles 
2013-
present 
Efficacious Unknown  No 
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